Search

Your search keyword '"Eich, Hans T."' showing total 7 results
Start Over Author "Eich, Hans T." Publisher wiley
7 results on '"Eich, Hans T."'

1. S2k-Guidelines - Cutaneous lymphomas (ICD10 C82-C86): Update 2021

Author

Dippel, Edgar, Assaf, Chalid, Becker, Juergen C., von Bergwelt-Baildon, Michael, Bernreiter, Sophie, Cozzio, Antonio, Eich, Hans T., Elsayad, Khaled, Follmann, Markus, Grabbe, Stephan, Hillen, Uwe, Klapper, Wolfram, Klemke, Claus-Detlev, Loquai, Carmen, Meiss, Frank, Mitteldorf, Christina, Wehkamp, Ulrike, Nashan, Dorothee, Nicolay, Jan P., Oschlies, Ilske, Schlaak, Max, Stranzenbach, Rene, Moritz, Rose, Stoll, Christoph, Vag, Tibor, Weichenthal, Michael, Wobser, Marion, Stadler, Rudolf, Dippel, Edgar, Assaf, Chalid, Becker, Juergen C., von Bergwelt-Baildon, Michael, Bernreiter, Sophie, Cozzio, Antonio, Eich, Hans T., Elsayad, Khaled, Follmann, Markus, Grabbe, Stephan, Hillen, Uwe, Klapper, Wolfram, Klemke, Claus-Detlev, Loquai, Carmen, Meiss, Frank, Mitteldorf, Christina, Wehkamp, Ulrike, Nashan, Dorothee, Nicolay, Jan P., Oschlies, Ilske, Schlaak, Max, Stranzenbach, Rene, Moritz, Rose, Stoll, Christoph, Vag, Tibor, Weichenthal, Michael, Wobser, Marion, and Stadler, Rudolf

Published
2022

2. S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021

Author

Dippel, Edgar, primary, Assaf, Chalid, additional, Becker, Jürgen C., additional, von Bergwelt‐Baildon, Michael, additional, Bernreiter, Sophie, additional, Cozzio, Antonio, additional, Eich, Hans T., additional, Elsayad, Khaled, additional, Follmann, Markus, additional, Grabbe, Stephan, additional, Hillen, Uwe, additional, Klapper, Wolfram, additional, Klemke, Claus‐Detlev, additional, Loquai, Carmen, additional, Meiss, Frank, additional, Mitteldorf, Christina, additional, Wehkamp, Ulrike, additional, Nashan, Dorothee, additional, Nicolay, Jan P., additional, Oschlies, Ilske, additional, Schlaak, Max, additional, Stranzenbach, René, additional, Moritz, Rose, additional, Stoll, Christoph, additional, Vag, Tibor, additional, Weichenthal, Michael, additional, Wobser, Marion, additional, and Stadler, Rudolf, additional

Published
2022
Full Text
View/download PDF

3. S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021

Author

Dippel, Edgar, primary, Assaf, Chalid, additional, Becker, Jürgen C., additional, von Bergwelt‐Baildon, Michael, additional, Bernreiter, Sophie, additional, Cozzio, Antonio, additional, Eich, Hans 
T., additional, Elsayad, Khaled, additional, Follmann, Markus, additional, Grabbe, Stephan, additional, Hillen, Uwe, additional, Klapper, Wolfram, additional, Klemke, Claus‐Detlev, additional, Loquai, Carmen, additional, Meiss, Frank, additional, Mitteldorf, Christina, additional, Wehkamp, Ulrike, additional, Nashan, Dorothee, additional, Nicolay, Jan P., additional, Oschlies, Ilske, additional, Schlaak, Max, additional, Stranzenbach, René, additional, Moritz, Rose, additional, Stoll, Christoph, additional, Vag, Tibor, additional, Weichenthal, Michael, additional, Wobser, Marion, additional, and Stadler, Rudolf, additional

Published
2022
Full Text
View/download PDF

4. Renaissance of Radiotherapy in Intestinal Lymphoma? 10‐Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow‐up of Two German Multicenter Consecutive Prospective Phase II Trials

Author

Reinartz, Gabriele, primary, Molavi Tabrizi, Caroline, additional, Liersch, Ruediger, additional, Ullerich, Hansjoerg, additional, Hering, Dominik, additional, Willborn, Kay, additional, Schultze, Juergen, additional, Micke, Oliver, additional, Ruebe, Christian, additional, Fischbach, Wolfgang, additional, Bentz, Martin, additional, Daum, Severin, additional, Pott, Christiane, additional, Tiemann, Markus, additional, Moeller, Peter, additional, Neubauer, Andreas, additional, Wilhelm, Martin, additional, Lenz, Georg, additional, Berdel, Wolfgang E., additional, Willich, Normann, additional, and Eich, Hans T., additional

Published
2020
Full Text
View/download PDF

5. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group

Author

Broeckelmann, Paul J., Goergen, Helen, Fuchs, Michael, Kriz, Jan, Semrau, Robert, Baues, Christian, Kobe, Carsten, Behringer, Karolin, Eichenauer, Dennis A., von Tresckow, Bastian, Klimm, Beate, Halbsguth, Teresa, Wongso, Diana, Pluetschow, Annette, Haverkamp, Heinz, Dietlein, Markus, Eich, Hans T., Stein, Harald, Diehl, Volker, Borchmann, Peter, Engert, Andreas, Broeckelmann, Paul J., Goergen, Helen, Fuchs, Michael, Kriz, Jan, Semrau, Robert, Baues, Christian, Kobe, Carsten, Behringer, Karolin, Eichenauer, Dennis A., von Tresckow, Bastian, Klimm, Beate, Halbsguth, Teresa, Wongso, Diana, Pluetschow, Annette, Haverkamp, Heinz, Dietlein, Markus, Eich, Hans T., Stein, Harald, Diehl, Volker, Borchmann, Peter, and Engert, Andreas

Abstract

Accurate clinical staging is crucial for adequate risk-adapted treatment in Hodgkin lymphoma (HL) to prevent patients from under- or over-treatment. Within the latest German Hodgkin Study Group trial generation, diagnostic findings such as histopathology, computerized tomography imaging and clinical risk factors were re-evaluated by expert panels. Here, we retrospectively analysed 5965 patients and identified 399 in who major discordant findings changed their first-line treatment allocation. Histopathology review did not confirm the initial diagnosis of HL in 87 patients. Treatment allocation was revised in 312 of the remaining 5878 patients: 176 were assigned to a higher and 128 to a lower risk group, respectively; the correct treatment group remained unclear in 8 patients. Cases of revised treatment allocation accounted for 9.8%, 6.0%, 0.8%, and 14.8% of patients initially assigned to the HD13, HD14, HD15 trials and stage IA lymphocyte-predominant HL project, respectively. Most revisions were due to wrong application of clinical stage (20.5% of 312 patients with revised treatment group), histological subtype (9.0%) or the risk factors 3 involved areas (46.8%) or large mediastinal mass (9.3%). In conclusion, centralized review by experienced experts changed risk-adapted first-line treatment in a relevant proportion of HL patients. Quality control measures clearly improve the accuracy of treatment and should be implemented in clinical practice.

Published
2015

6. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Fuchs, Michael, additional, Kriz, Jan, additional, Semrau, Robert, additional, Baues, Christian, additional, Kobe, Carsten, additional, Behringer, Karolin, additional, Eichenauer, Dennis A., additional, von Tresckow, Bastian, additional, Klimm, Beate, additional, Halbsguth, Teresa, additional, Wongso, Diana, additional, Plütschow, Annette, additional, Haverkamp, Heinz, additional, Dietlein, Markus, additional, Eich, Hans T., additional, Stein, Harald, additional, Diehl, Volker, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results